Mohammad Fazel

Interests

No activities entered.

Courses

Scholarly Contributions

Journals/Publications

• Alamer, A., Alyazidi, W., Aldosari, S., Mobarki, F., Almakki, S., Alahmari, A., Alomar, M., Almalki, Z., Alkaff, T., & Fazel, M. (2024). Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia. Journal of Dermatological Treatment, 35(1). doi:10.1080/09546634.2024.2386973
  More info

  Background: Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation. Objectives: To identify physicians’ prescribing patterns of biological therapies at a referral tertiary center in Saudi Arabia and assess the probability of biologic persistence following treatment initiation. Methods: We conducted a retrospective study of biologic-naïve adult psoriasis patients who initiated therapy from October 2013 to July 2022 in Dammam. Descriptive statistics and a Kaplan-Meier analysis evaluated treatment persistence at 6, 12, 24, and 36 months. Results: A total of 151 patients received adalimumab (n = 89), etanercept (n = 17), risankizumab (n = 30), ustekinumab (n = 14), and ixekizumab (n = 1). At 6 months, all therapies demonstrated 100% persistence. At 12 months, persistence was highest for ustekinumab (100%) and lowest for etanercept (88.2%). At 24 months, ustekinumab maintained 100% persistence, followed by risankizumab (96.6%), adalimumab (94.3%), and etanercept (76.4%). At 36 months, risankizumab had the highest persistence (96.6%), followed by adalimumab (83.1%), ustekinumab (78%), and etanercept (70.6%). The most common reasons for discontinuation were lack of effectiveness and intolerability. Conclusion: This study shows changing psoriasis treatment patterns with new therapies. Risankizumab demonstrated high long-term persistence, while etanercept and ustekinumab showed declining persistence, suggesting evolving treatment considerations.
• Alamer, A., Alyazidi, W., Aldosari, S., Mobarki, F., Almakki, S., Alahmari, A., Alomar, M., Almalki, Z., Alkaff, T., & Fazel, M. (2024). Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia. The Journal of dermatological treatment, 35(1), 2386973.
  More info

  Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.
• Dagenet, C. B., Davis, M. S., Murphy, S., Thiede, R., Culpepper, K. S., & Fazel, M. (2023). Limited Cutaneous Leishmaniasis as Ulcerated Verrucous Plaque on Leg, Tucson, Arizona, USA. Emerging infectious diseases, 29(6), 1268-1269.
  More info

  We report a 34-year-old man who had a nonhealing, verrucous plaque with central ulceration on the lower leg. This case-patient is a rare example of endemic limited cutaneous leishmaniasis in Tucson, Arizona, USA. Clinicians should be aware of this disease because its manifestations can vary for individual patients.
• Fernandez, J. M., Mata, E. M., Erdrich, J., & Fazel, M. (2023). Retrospective Cohort Analysis of Sex Differences in American Indians and Alaska Natives With Invasive Melanoma From the National Cancer Database. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 49(11), 1039-1041.
• Jedlowski, P. M., Jedlowski, M. F., & Fazel, M. (2023). Medications affecting the insulin-like growth factor 1/growth hormone axis, including teprotumumab, somatostatin analogs, and anti-calcitonin gene-related peptide monoclonal antibodies, are associated with elevated reporting odds of alopecia in women: A pharmacovigilance study. Journal of the American Academy of Dermatology, 89(2), 408-410.
• Thiede, R. M., Fazel, M., MacDonald, K. M., & Abraham, I. (2022). Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?. Expert opinion on pharmacotherapy, 23(14), 1563-1567.
• Fazel, M., AlRawashdh, N., Alamer, A., Curiel-Lewandrowski, C., & Abraham, I. (2021). Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma. Expert opinion on biological therapy, 21(12), 1647-1653.
  More info

  Talimogene laherparepvec (T-VEC) improves overall survival (OS) in unresectable stage IIIB/C-IV melanoma T-VEC may have synergistic effects with CTLA-4 inhibitors In the absence of a trial comparing T-VEC and ipilimumab (T-VEC + IPI) to T-VEC, we applied a novel indirect comparison method using extrapolated OS curves to estimate OS outcomes in a simulated trial comparing both regimens in stage IIIB/C-IV unresectable melanoma.
• Fazel, M., Cooley, J., Kurdi, S., & Fazel, M. (2019). A co-curricular diabetes-specific elective with interprofessional students and faculty. Currents in pharmacy teaching & learning, 11(2), 172-177.
  More info

  Develop and assess the effectiveness of an interprofessional co-curricular elective in improving pharmacy students' confidence in providing diabetes self-management education and support (DSMES) to patients.
• Fazel, M. T., Fazel, M., Bedrossian, N. L., Picazo, F., Sobel, J. D., Fazel, M., Te, C., & Pendergrass, M. L. (2017). Impact of supplemental training programs on improving medical students' confidence in providing diabetes self-management education and support. Advances in medical education and practice, 8, 675-680.
  More info

  The purpose of this study was to evaluate the effectiveness of supplemental diabetes-related training modalities and volunteer activities in increasing first-year medical students' knowledge/comfort in providing diabetes self-management education and support (DSMES) to patients.
• Justiniano, R., Perer, J., Hua, A., Fazel, M., Krajisnik, A., Cabello, C. M., & Wondrak, G. T. (2017). A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse Skin. Photochemistry and photobiology, 93(6), 1472-1482.
  More info

  Nonmelanoma skin cancer (NMSC) is the most common malignancy in the United States representing a considerable public health burden. Pharmacological suppression of skin photocarcinogenesis has shown promise in preclinical and clinical studies, but more efficacious photochemopreventive agents are needed. Here, we tested feasibility of harnessing pharmacological disruption of intracellular zinc homeostasis for photochemoprevention in vitro and in vivo. Employing the zinc ionophore and FDA-approved microbicidal agent zinc pyrithione (ZnPT), used worldwide in over-the-counter (OTC) topical consumer products, we first demonstrated feasibility of achieving ZnPT-based intracellular Zn overload in cultured malignant keratinocytes (HaCaT-ras II-4; SCC-25) employing membrane-permeable fluorescent probes. Zinc overload was accompanied by induction of intracellular oxidative stress, associated with mitochondrial superoxide release as substantiated by MitoSOX Red™ fluorescence microscopy. ZnPT-induced cell death observable in malignant keratinocytes was preceded by induction of metal (MT2A), proteotoxic (HSPA6, HSPA1A, DDIT3, HMOX1) and genotoxic stress response (GADD45A, XRCC2) gene expression at the mRNA and protein levels. Comet analysis revealed introduction of formamidopyrimidine-DNA glycosylase (Fpg)-sensitive oxidative DNA lesions. In a photocarcinogenesis model (UV-exposed SKH-1 high-risk mouse skin), topical ZnPT administration post-UV caused epidermal zinc overload and stress response gene expression with pronounced blockade of tumorigenesis. Taken together, these data suggest feasibility of repurposing a topical OTC drug for zinc-directed photochemoprevention of solar UV-induced NMSC.
• Fazel, M. T., Fazel, M., Bedrossian, N. L., Picazo, F., & Pendergrass, M. L. (2016). A student-implemented elective to improve medical student confidence in providing diabetes self-management support. Advances in medical education and practice, 7, 567-570.
  More info

  The purpose of this study was to develop a preclerkship elective and assess its effectiveness in supplementing medical students' education.

Others

• Fazel, M. (2023, 5). Papulopustular facial eruption in the Setting of Vandetanib.